These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35953563)

  • 1. Lower buprenorphine elimination rate constant is associated with lower opioid use.
    Elarabi HF; Lee AJ; Adem A; Elrasheed A; Marsden J; Al Ghaferi H
    Psychopharmacology (Berl); 2022 Oct; 239(10):3213-3221. PubMed ID: 35953563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial.
    Elarabi HF; Shawky M; Mustafa N; Radwan D; Elarasheed A; Yousif Ali A; Osman M; Kashmar A; Al Kathiri H; Gawad T; Kodera A; Al Jneibi M; Adem A; Lee AJ; Marsden J
    Addiction; 2021 Sep; 116(9):2398-2408. PubMed ID: 33404141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
    Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
    Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
    Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
    Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
    Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management.
    Elarabi H; Elrasheed A; Ali A; Shawky M; Hasan N; Gawad TA; Adem A; Marsden J
    J Addict; 2019; 2019():2491063. PubMed ID: 30956839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysubstance Use in Adults With Opioid Use Disorder Receiving Buprenorphine Maintenance.
    Elarabi HF; Radwan DN; Adem A; Marsden J; Lee AJ
    J Addict Med; 2023 Jan-Feb 01; 17(1):74-78. PubMed ID: 35793664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
    Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
    Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory Economic Evaluation of Buprenorphine Treatment in Opioid Use Disorder.
    Elarabi HF; Al Ghaferi H; Hasan N; Lee AJ; Shawky M; Al Kathiri H; Elrasheed A; Al Maamari S; Gawad TA; Radwan D; Adem A; Marsden J
    J Ment Health Policy Econ; 2021 Sep; 24(3):89-95. PubMed ID: 34554106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
    Gerra G; Borella F; Zaimovic A; Moi G; Bussandri M; Bubici C; Bertacca S
    Drug Alcohol Depend; 2004 Jul; 75(1):37-45. PubMed ID: 15225887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.